Credit: Shutterstock photoHealthcare stocks reversed narrow losses earlier today and were ending slightly higher with the NYSE Healthcare Sector Index adding about 0.1% and shares of healthcare companies in the S&P 500 gaining about 0.2% as a group.
In company news, shares of Cross Country Healthcare ( CCRN ) rose Tuesday after the healthcare staffing firm announced a deal to acquire Medical Staffing Network for around $48.3 million, subject to post-closing adjustments for working capital.
The target company currently has 55 U.S. locations providing per diem, contract and permanent hire staffing services, generating around $229 million in revenue during the 12 months ended Dec. 31, and another $78 million in revenue during the first four months of 2014.
CCRN said it expects the deal to trim its expected FY14 earnings by $0.10 to $0.12 per share, largely due to acquisition and integration charges, while boosting its FY15 earnings by $0.12 to $0.15 per share. Analysts currently are projecting the company to produce EPS of $0.08 this year and earning $0.27 per share in FY15, according to Capital IQ.
CCRN shares were ahead nearly 7% at $6.05 each late in Tuesday's session, earlier climbing to an intra-day high of $6.14 a share. The stock has a 52-week range of $4.83 to $11.54 a share, rising about 11.2% over the past 12 months.
In other sector news,
(+) BIOC, Aegis Capital begins coverage with a Buy recommendation and a $16 price target. The company yesterday expanded its OncoCEE-BR test platform to include estrogen receptors.
(-) THRX, Late Monday completes separation of its late-stage partnered respiratory assets from its Teravance Biopharma ( TBPH ) operations, creating two publicly traded companies. TBPH is steady at $19.51 a share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
